A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Alterome Therapeutics, Inc.
Pfizer
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)